261 related articles for article (PubMed ID: 25786394)
21. Combination of furosemide and metolazone in the treatment of severe congestive heart failure.
Grosskopf I; Rabinovitz M; Rosenfeld JB
Isr J Med Sci; 1986 Nov; 22(11):787-90. PubMed ID: 3793436
[TBL] [Abstract][Full Text] [Related]
22. Furosemide (Lasix).
Med Lett Drugs Ther; 1972 Aug; 14(17):63-4. PubMed ID: 4567565
[No Abstract] [Full Text] [Related]
23. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
Dormans TP; van Meyel JJ; Gerlag PG; Tan Y; Russel FG; Smits P
J Am Coll Cardiol; 1996 Aug; 28(2):376-82. PubMed ID: 8800113
[TBL] [Abstract][Full Text] [Related]
24. Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?
Zacharias H; Raw J; Nunn A; Parsons S; Johnson M
Palliat Med; 2011 Sep; 25(6):658-63. PubMed ID: 21398345
[TBL] [Abstract][Full Text] [Related]
25. Comparison of three diuretic treatment strategies for patients with acute decompensated heart failure.
Yayla Ç; Akyel A; Canpolat U; Gayretli Yayla K; Eyiol A; Akboğa MK; Türkoğlu S; Tavil Y; Boyacı B; Çengel A
Herz; 2015 Dec; 40(8):1115-20. PubMed ID: 26135463
[TBL] [Abstract][Full Text] [Related]
26. Inferior vena cava diameter change after intravenous furosemide in patients diagnosed with acute decompensated heart failure.
Tchernodrinski S; Lucas BP; Athavale A; Candotti C; Margeta B; Katz A; Kumapley R
J Clin Ultrasound; 2015 Mar; 43(3):187-93. PubMed ID: 24897939
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with low-dose continuous infusion of furosemide in acute heart failure: assessment of efficacy and safety.
Ng TM; Hshieh S; Chan CY; Elkayam U
J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):373-81. PubMed ID: 22610091
[TBL] [Abstract][Full Text] [Related]
28. Lowering of furosemide dosage after clinical stabilization in patients with congestive heart failure.
Alexopoulos GP; Anastasiou-Nana MI; Rapti ACh; Margari ZJ; Terrovitis JV; Mitsibounas D; Makri S; Nanas JN
Acta Cardiol; 2003 Dec; 58(6):513-7. PubMed ID: 14713176
[TBL] [Abstract][Full Text] [Related]
29. Subcutaneous furosemide patch: heart failure decongestion 'from the comfort of your home'.
Dimitriadis K; Pyrpyris N; Tsioufis K
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):259-260. PubMed ID: 38289722
[No Abstract] [Full Text] [Related]
30. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience.
Zatarain-Nicolás E; López-Díaz J; de la Fuente-Galán L; García-Pardo H; Recio-Platero A; San Román-Calvar JA
Rev Esp Cardiol (Engl Ed); 2013 Dec; 66(12):1002-4. PubMed ID: 24774118
[No Abstract] [Full Text] [Related]
31. Pharmacokinetics and diuretic effect of furosemide after single intravenous, oral tablet, and newly developed oral disintegrating film administration in healthy beagle dogs.
Koh SK; Jeong JW; Choi SI; Kim RM; Koo TS; Cho KH; Seo KW
BMC Vet Res; 2021 Sep; 17(1):295. PubMed ID: 34488750
[TBL] [Abstract][Full Text] [Related]
32. Preventable delays to intravenous furosemide administration in the emergency department prolong hospitalization for patients with acute heart failure.
Ward MJ; Collins SP; Liu D; Froehle CM
Int J Cardiol; 2018 Oct; 269():207-212. PubMed ID: 30041982
[TBL] [Abstract][Full Text] [Related]
33. What are the effects of hypertonic saline plus furosemide in acute heart failure?
Zepeda P; Rain C; Sepúlveda P
Medwave; 2015 Aug; 15 Suppl 2():e6233. PubMed ID: 26335942
[TBL] [Abstract][Full Text] [Related]
34. Hyperacute leucopenia associated with furosemide.
Ma BJ
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29167185
[TBL] [Abstract][Full Text] [Related]
35. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
Kurien S; Warfield KT; Wood CM; Miller WL
Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
[TBL] [Abstract][Full Text] [Related]
36. Treatment of subclinical fluid retention in patients with symptomatic heart failure: effect on exercise performance.
Chomsky DB; Lang CC; Rayos G; Wilson JR
J Heart Lung Transplant; 1997 Aug; 16(8):846-53. PubMed ID: 9286777
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of diuretic dose in chronic heart failure.
Martins J; Lourenço P; Araújo JP; Mascarenhas J; Lopes R; Azevedo A; Bettencourt P
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):185-91. PubMed ID: 21335479
[TBL] [Abstract][Full Text] [Related]
38. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation.
van der Vorst MM; den Hartigh J; Wildschut E; Tibboel D; Burggraaf J
Crit Care; 2007; 11(5):R111. PubMed ID: 17925044
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacodynamics of piretanide in compromised kidney function. Dose response relationship and equipotency with furosemide].
Keller E; Reetze-Bonorden P; Rambauseck M; Pooth R
Internist (Berl); 1992 Aug; 33 Suppl 1():S36-8. PubMed ID: 1428696
[No Abstract] [Full Text] [Related]
40. Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure.
Olesen KH; Sigurd B; Steiness E; Leth A
Acta Med Scand; 1973; 193(1-2):119-31. PubMed ID: 4574445
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
